帕利哌酮缓释片与利培酮治疗精神分裂症的临床分析

Clinical analysis of paliperidone extended-release tablets and risperidone in treatment of schizophrenia

目的剖析帕利哌酮缓释片与利培酮对精神分裂症患者临床症状、社会功能与疗效的影响,供临床借鉴。方法选择44例精神分裂症患者作为研究对象,采用随机分组的方法,对本研究组的所有患者进行分组,划分的组别分别为观察组和对照组,每组22例。对照组患者主要采用利培酮进行治疗,观察组患者主要采用帕利哌酮缓释片进行治疗。观察两组用药后病情的改善情况,比较社会功能量表评分与疗效等治疗指标。结果治疗后4周,观察组患者的阳性与阴性症状量表(PAMSS)减分率为(54.7±12.3)、临床疗效总评量表(CGI)减分率为(56.4±14.6)、社会功能量表(PSP)分值为(55.7±32.5)分,对照组分别为(40.8±14.2)、(44.6±11.8)(26.8±17.9)分。观察组明显优于对照组,两组比较差异明显有统计学意义(P<0.05)。结论临床上治疗精神分裂症患者,采用帕利哌酮缓释片进行治疗效果更好,能够提高患者治疗的有效率,促进患者的预后,提升患者的生活质量,改善患者的社会功能,具有临床推广使用价值。

Objective To analyze the influences of paliperidone extended-release tablets and risperidone on the clinical symptoms,social functionsand effects for schizophrenia patients,so as to provide guidance.Methods44cases of schizophrenia patients were selected as the study objects,and were randomly divided into the observation group and control group.22cases in each group.The control group were given reperidone therapy,and the observation group mainly given paliperidone extended-release tablets therapy.The disease improvement in these two groups after thedrugs was observed,and the treatment indicators such as social functions rating scale scores and effects were compared.Results4weeks after thetreatment,the positive and negative symptom score(PAMSS)was(54.7±12.3),the clinical efficacy rating scale(CGI)was(56.4±14.6),the socialfunction scale(PSP)score was(55.7±32.5)in the observation group,and control group(40.8±14.2),(44.6±11.8),(26.8±17.9)points,with significantdifferences(P<0.05).Conclusion The paliperidone extended-release tablets in the treatment of schizophrenia patients can obtain better treatment effects,improve the treatment effective rate,promote the prognosis,improve the life quality and social functions,and is worthy of clinical promotion.